The new normal in US oncology approvals
Nearly two thirds of key oncology filings are expedited; and what about the ones that aren’t?
Nearly two thirds of key oncology filings are expedited; and what about the ones that aren’t?
MorphoSys, Blueprint and Syndax celebrate a successful ASH; Cogent not so much.
But the FDA’s investigation looks like worse news for autoimmune disease than oncology.
Arcellx climbs 19%, but the most significant Car-T presentation at ASH might not even be in oncology.